Notifications about medicines to healthcare professionals
-
Register-based study suggests a slightly increased risk of meningiomas in women using hormonal contraception containing a progestogen
| 03 July 2026 |
A study of 25 years of data from Danish women aged 15-59 suggests that meningiomas (tumours of the meninges) may be a very rare side effect of contraceptives containing a progestogen. The Danish Medicines Agency is therefore raising a safety signal in the European Pharmacovigilance Risk Assessment Committee (PRAC).
-
EMA’s Human Medicines Committee Recommends Wegovy in Tablet Form
| 22 May 2026 |
EMA’s human medicines committee (CHMP), part of the European Medicines Agency, decided at its meeting this week to recommend approval of Wegovy in tablet form. It is now for the European Commission to make the final decision.
-
PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy
| 19 March 2026 |
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommends that the product information for semaglutide medicines should include information that the rare eye condition NAION could be a very rare side effect. Treatment should be stopped if symptoms of NAION occur.